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Abstract
Background The extent to which economic evaluations
have included the healthcare resource and outcome-related
implications of information provision in national newborn
bloodspot screening programmes (NBSPs) is not currently
known.
Objectives To identify if, and how, information provision
has been incorporated into published economic evaluations
of NBSPs.
Methods A systematic review of economic evaluations of
NBSPs (up to November 2014) was conducted. Three elec-
tronic databases were searched (Ovid: Medline, Embase,
CINAHL) using an electronic search strategy combining a
published economic searchfilterwith terms related to national
NBSPs and screening-related technologies. These electronic
searcheswere supplemented by searching theNHSEconomic
Evaluations Database (NHS EED) and hand-searching iden-
tified study reference lists. The results were tabulated and
summarised as part of a narrative synthesis.
Results A total of 27 economic evaluations [screening-
related technologies (n = 11) and NBSPs (n = 16)] were
identified. The majority of economic evaluations did not
quantify the impact of information provision in terms of
healthcare costs or outcomes. Five studies did include an
estimate of the time cost associated with information pro-
vision. Four studies included a value to reflect the disutility
associated with parental anxiety caused by false-positive
results, which was used as a proxy for the impact of im-
perfect information.
Conclusion A limited evidence base currently quantifies
the impact of information provision on the healthcare costs
and impact on the users of NBSPs; the parents of new-
borns. We suggest that economic evaluations of expanded
NBSPs need to take account of information provision
otherwise the impact on healthcare costs and the outcomes
for newborns and their parents may be underestimated.
Key Points for Decision Makers
The process of information provision as part of a
national bloodspot screening programme, with an
increasing emphasis on expanding the programme to
include more conditions, is likely to have
implications in terms of healthcare resource use and
also subsequent health and non-health outcomes.
Few economic evaluations of NBSPs attempt to
quantify the cost of providing information about the
programme, or the impact of this information
provision on parents and newborns.
Research is needed to generate robust data on the
actual cost of information provision for healthcare
services, the impact of NBSPs on subsequent use of
healthcare services and the impact on parents’ health
status and ability to make an informed decision in the
context of expanded NBSPs.
Electronic supplementary material The online version of this
article (doi:10.1007/s40258-015-0177-2) contains supplementary
material, which is available to authorized users.
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1 Introduction
Newborn bloodspot screening (NBS) is viewed as one of
the greatest public health developments of the twentieth
century [1]. The procedure involves obtaining a sample of
blood from the newborn baby, usually by taking drops of
blood from the heel, and using this sample (bloodspots),
stored on a collection card, to screen for a number of pre-
specified inherited conditions. Screening aims to facilitate
the early detection of these inherited conditions and hence
allow for the timely initiation of treatment to help prevent
or manage the extent of subsequent impact on the health of
the newborn baby.
The Guthrie method was developed during the late
1950s by Dr Robert Guthrie, and aims to detect pheny-
lalanine, phenylpyruvic acid, and phenyllactic acid in
dried bloodspots stored on a card [2]. The Guthrie method
allowed the detection of inborn errors of metabolism, the
first being the detection of phenylketonuria (PKU). Tan-
dem mass spectrometry (MS/MS) was developed in the
early 1990s to speed up the identification of inborn errors
of metabolism and could be adapted to the Guthrie col-
lection protocols [3]. As a result, MS/MS became a more
appropriate technology for use in newborn bloodspot
screening programmes (NBSPs) provided at a national
level [4]. The introduction of MS/MS technology in the
UK in 2007 dramatically increased the number of in-
herited conditions which could potentially be screened for
in newborn babies. However, despite the apparently low
unit cost of introducing new conditions into existing na-
tional screening programmes, there are associated costs in
terms of communication, events which are rarely ac-
counted for. Furthermore, the potential scale of population
level screening programmes means that small incremental
unit costs can add up to large total costs for healthcare
providers. For example, in the UK, the NBSP, that
screens approximately 800,000 babies a year [5], has a
substantial impact on the healthcare budget in terms of
the cost of providing the service and the potential to in-
fluence long-term use of healthcare resources. The po-
tential impact on scarce healthcare resources and the need
to understand the opportunity cost of changing or ex-
panding NBSPs has stimulated the production of a
growing literature that applies methods of economic
evaluation to help policy makers decide which specific
conditions should be included in a NBSP. The ultimate
aim of these economic evaluations is to guide whether the
proposed NBSP is a cost-effective use of finite healthcare
resources.
NBSPs across the world differ in the conditions
screened for (see Supplementary Appendix 2) and their
requirement of obtaining parental consent. Internationally,
there is increasing appreciation of the centrality of com-
munication in ensuring that NBSP benefits are realised
whilst reducing potential harms [6–15]. Specifically, there
is a recognised need to inform parents prior to screening
[16–18], preferably antenatally [16, 19]. In contrast, cur-
rent NBSPs do not have explicit models of information
provision after positive test results beyond setting up ap-
propriate referral to the service to care for the condition
diagnosed. A failure to provide adequate information,
when parents are deciding whether to take part in the
NBSP, and understand the implications of a test result, may
result in costs (or dis-benefits) to parents as well as the
healthcare provider. For example, there is the suggestion
that parents may not make ‘informed decisions’ about
screening as although they consent to screening occurring
many are not aware that screening has occurred [20–24] or
have limited knowledge about it [16, 25–29]. Poor com-
munication of key pieces of information can result in ad-
ditional anxiety and distress when unexpected results are
received [30, 31], which in turn has been shown to impact
on health, relationships, ability to work and engagement in
society [32]. The cause of anxiety is likely to be multi-
factorial. However, there may be identifiable and quan-
tifiable consequences of anxiety in terms of the use of
healthcare services in terms of additional consultations
needed by parents to deal with the sequelae of anxiety
resulting from poor information provision [32]. As NBSPs
include increasingly rare diseases with less clear treatment
benefits, communication will become ever more critical
both before and after screening [33]. In summary, it is
apparent that the process of information provision as part
of a national bloodspot screening programme, with an in-
creasing emphasis on expanding the programme to include
more conditions, is likely to have implications in terms of
healthcare resource use and also subsequent health and
non-health outcomes, such as informed decision making.
Langer et al. [34], produced a set of guidelines to inform
the design and conduct of an economic evaluation of an
NBSP, which were then applied to published economic
evaluations of NBSP for metabolic diseases up to 2011.
The authors concluded that the published evaluations were
generally poor at measuring and valuing resource data or
considering non-health outcomes. This review, however,
did not explicitly identify whether the published evalua-
tions included information provision in terms of (1) the
impact on resource use, or (2) valuation of the impact on
outcomes. The aim of this current study is to identify the
extent to which economic evaluations of NBSP take into
account the role of information provision and its
consequences.
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2 Methods
A systematic review was carried out to identify all pub-
lished economic evaluations of NBSP provided on a na-
tional basis and associated specific screening technologies.
The review was conducted according to published methods
[35] and followed the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) Checklist.
2.1 Literature Search
The electronic databases used to search for relevant pub-
lished economic evaluations included Ovid Medline, Ovid
Embase, Ovid CINAHL and NHS Economic Evaluations
Database (NHS EED). The electronic search strategies
were specifically designed for each database by combing
relevant index and free-text terms for NBS (identified by
the literature) with economic evaluation search filters de-
veloped by the Centre for Reviews and Dissemination
(CRD) [36]. The searches were verified by a researcher
who has worked in the field of NBS (FU) and an infor-
mation specialist (personal communication, Mary Ingram;
July 2013). Supplementary Appendix 1 details the elec-
tronic search strategies. The electronic searches were
supplemented by examining the reference lists of each
identified study. All searches were conducted in November
2014.
2.2 Inclusion Criteria and Study Selection
for Critical Review
The identified economic evaluations, titles and abstracts,
were screened by three independent reviewers to assess
whether the study satisfied the criteria specified for inclu-
sion in the review (see Table 1). All types of economic
evaluations (cost-effectiveness; cost-utility and cost-benefit
analysis) and either model-based or retrospective economic
analyses based on cohort studies were eligible for inclusion
in the review.
2.3 Data Extraction and Synthesis
Two reviewers (CJ/SW) extracted the data from each
identified study using a structured data collection form. The
data extraction form was based on a checklist developed by
the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) [37]. The data extracted incorporated
the (1) author, year of publication and country in which the
study was conducted, (2) viewpoint and population, (3)
type of evaluation vehicle used, (4) resources used, (5)
valuation of the cost of information provision, (6) valuation
of benefits, including health and non-health outcomes, and
finally (7) key results. The results were tabulated and
summarised as part of a narrative synthesis.
3 Results
Figure 1 summarises the study identification and inclusion
process. A total of 27 economic evaluations were identified
and included in this review. Of these studies, 11 evaluated
screening technologies used in NBSPs [17, 38–47] (see
Supplementary Appendix 3) and 16 evaluated NBSPs [6,
48–62] (see Supplementary Appendix 4). A summary of
the conditions presently screened for in each country is
provided in Supplementary Appendix 2 to place the
evaluations into context.
3.1 Types of NBSP
Newborn screening programmes were defined as a service
which includes the provision of information, collection of
informed consent (where appropriate to the jurisdiction),
collection of samples, use of technology to analyse the
sample, provision of test results and an appropriate referral
mechanism to subsequent services if a positive test result is
confirmed. It is important to distinguish between evalua-
tions that focus on the technology used to run the analysis
compared with those that evaluate a NBSP as a whole
Table 1 Summary of study inclusion criteria
Aspect of study Inclusion criteria
Study Design Full economic evaluation in accordance with definition by Drummond et al. [78]: cost-effectiveness
analysis (CEA); cost-utility analysis (CUA); cost-benefit analysis (CBA)
Population Neonates, infants, children
Intervention National newborn screening programme for inherited diseases or a specific screening technology
Type Model-based or prospective/retrospective (RCT or cohort) evaluation
Outcomes Costs (health and/or patient)
Health and non-health patient benefits
Availability English; full text
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service because the appropriate study perspective and time
horizon for the analysis is likely to be different.
Sixteen studies were identified as economic evaluations
of NBSPs and clearly described the programmes included
in the analysis. The studies identified that evaluated NBSPs
were based in a number of different countries including:
the USA (n = 8); The Netherlands (n = 4); Australia
(n = 1), Libya (n = 1), France (n = 1) and the UK
(n = 1). Not all countries providing NBSPs have the same
policies regarding informed consent, the country of origin
for the evaluation is key to understanding if, and how,
informed consent has been considered. The North Amer-
ican studies included are based in the States of Indiana,
Alaska, Texas and Kentucky. All four of these states allow
parents to refuse a screening test based on religious
grounds [63]. Four studies are based in Australia, France,
The Netherlands and the UK, all of which require parental
consent prior to performing a screening test. It was not
made clear what level of informed consent is required in
Libya.
Seven studies discussed the implications of using dif-
ferent screening strategies, for example, universal or tar-
geted strategies [48, 50, 51, 53, 55, 59, 61]. Three studies
focused on expanded screening programmes to include
additional screening for medium-chain acyl-coenzyme A
dehydrogenase deficiency (MCADD) [6, 52, 58], three
studies reported screening strategies specifically for cystic
fibrosis (CF) [57, 62] and MCADD [60], respectively, and
two studies focussed on screening for severe combined
immunodeficiency (SCID) [49, 54].
Eight of the studies compared the NBSP with no
screening [48, 49, 51, 54–56, 60, 62]. The remaining eight
16 relevant NBS 
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Fig. 1 PRISMA flow diagram
of search results
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studies compared screening with existing strategies [6, 50,
52, 53, 57–59, 61].
3.2 Types of Screening Technologies
In the eleven economic evaluations of screening tech-
nologies, two types of technology were evaluated: the
Guthrie method [45] and tandem mass spectrometry [17,
38–44, 46–48].
The studies identified for this section of the review were
based in countries including: USA (n = 4); Canada
(n = 2); UK (n = 2); Iran (n = 1); Finland (n = 1); and
Australia (n = 1). The NBS technology studies carried out
in North America were based in the States of California,
Wisconsin, and Pennsylvania, all of which allow the re-
jection of the NBS test by parents on religious grounds
only [63]. The Canadian studies included in this review
were based in Ontario and Nova Scotia. Ontario largely
operates its NBS testing on an opt-out basis; however,
when new technologies are introduced formal consent is
required [64]. In contrast, in Nova Scotia the requirement
for consent varies from hospital to hospital [64]. Australia,
Finland and the UK all require informed consent before the
test can be carried out. In Iran, NBS screening is only
mandatory for one specific condition; congenital hypothy-
roidism (CH).
Shamshiri et al. [45] evaluated the cost effectiveness of
the Guthrie method compared with no screening, assuming
the perspective of the Iranian health service that, apart from
screening for CH, has a voluntary NBSP. Ten studies
conducted an economic evaluation of MS/MS. Four of
these studies reported using no screening as the relevant
comparator [38, 40, 41, 47] but did not justify why no
screening was the relevant comparator of choice. Four
studies compared new MS/MS with existing technologies
[17, 39, 42, 43] and supported their choice of comparator
by stating that it allowed for a direct comparison between
the cost effectiveness of new and existing screening tech-
nologies. Tran et al. [46] compared MS/MS screening with
clinical diagnosis. The study by Schoen et al. [44] did not
clearly specify a comparator but it can be inferred that no
screening was the alternative intervention.
3.3 Types of Economic Evaluation
Cost-effectiveness analysis (CEA) was the most common
type of economic evaluation (n = 8), followed by cost-
utility analysis (CUA) (n = 7) for studies evaluating
NBSPs. One study reported their findings using cost-benefit
analysis (CBA) [50]. CUA and CEA were similarly pop-
ular methods used to evaluate screening technologies
(CUA n = 7 and CEA n = 6) and one study [40] reported
a CBA using hedonic pricing methods to attach a monetary
value to the benefits of screening.
There were 24 model-based economic evaluations (14
NBSPs; 10 screening technologies). Of the 24 model-based
studies, 12 used a decision tree (7 NBSPs; 5 screening
technologies). Two studies used a Markov model (NBSPs)
and three studies combined a decision tree with a Markov
model (two NBSP; one screening technology). Two studies
(NBSPs) used patient level simulation models. Five studies
(one NBSPs; four screening technology) used a model-
based analysis but did not explicitly report the type of
model used. Three studies (two NBSPs; one screening
technology) used data collected as part of cohort studies to
inform the analysis.
3.4 Key Results of Evaluations
All of relevant studies concluded that MS/MS was a cost-
effective use of healthcare resources. Two papers [39, 43]
went further and stated that the relative cost effectiveness
of MS/MS was dependent on the number of conditions
being screened for and the results indicated that the com-
bined screening for PKU and MCADD was cost effective.
In total, 15 of the evaluations of NBSPs concluded the
programmes were a cost-effective use of resources.
Panepinto et al. [55] and Gessner et al. [51] both reported
that targeted screening with follow up was more cost ef-
fective than universal screening. Tiwana et al. [58], Hamers
and Rumeau-Pichon [52], Prosser et al. [6], Chan et al.
[49], McGhee et al. [54], Simpson et al. [57], Sladkevicius
et al. [56] and van der Hilst et al. [60] all reported that
introducing an expanded NBSP was cost effective. Van den
Akker-van Marle et al. [59], Wildhagen et al. [62] and
Wells et al. [61] reported the most cost-effective diagnosis
strategies.
3.5 Valuation of Benefits
All of the 27 studies focussed on the valuation of health
benefits alone. None of the studies included a measure of
non-health benefits, for example, the impact on the ability
to make an informed decision, which is synonymous with
‘cognitive capability’ (or empowerment [65]). A total of 11
cost-effectiveness analyses (five NBSPs; six screening
technologies) used life-years gained (LYG), or saved, to
value health benefits. Norman et al. [42] justified their use
of LYG together with ‘death-years averted’ by stating that
there was a lack of published credible utility weights for
newborns with the relevant conditions to ‘quality adjust’
the additional years of life from the screening intervention.
Pandor et al. [43] acknowledged the use of LYG may have
resulted in serious limitations in their study because it
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might have underestimated the potential benefits to be
gained from the NBSP. There was significant variation in
the way each study reported the estimation of LYG. Some
authors used multiple life expectancy (LE) estimates to
reflect the severity of the condition when calculating LYG
[39, 42–44, 52, 60].
Thirteen studies (seven NBSPs; six screening tech-
nologies) estimated quality-adjusted life years (QALYs) to
value the health benefits. Just six studies explicitly reported
the utility estimates and LE figures used to generate the
QALYs [41, 44, 48, 49, 52, 57]. Four of the studies [6, 40,
47, 58] did not explicitly report either the assumed impact
on LE or utility estimates used in the analyses. Feuchtbaum
and Cunningham [40] and Geelheod et al. [50] reported
their findings using monetary health benefits. Feuchtbaum
and Cunningham [40] valued the health benefits of NBS by
calculating the number of lives saved through MS/MS
screening and assigned a monetary value of each life saved
as reported from the US Environment Protection Agency.
Geelheod et al. [50] chose to value benefits in terms of the
expected costs of disability avoided through NBS.
3.6 Cost of Providing Information
Five studies [38, 43, 50, 57, 62] identified in this review
(three NBSPs; two screening technologies), included an
estimate of the cost of information provision in their ana-
lyses. None of the identified studies captured the impact of
information provision after a screening test had been
completed. Four of the five studies, which included a cost
of information provision, were model-based evaluations
while the other was a based on a retrospective cohort of
newborns. Costs were developed from a range of sources
including: cost data from existing programmes; the cost of
information provision in similar healthcare programmes
(for example information provision for prenatal or ante-
natal screening); the estimated time for a consultation with
a midwife; patient surveys; and general assumptions made
by the authors.
All five studies used different assumptions and methods
to estimate the cost of information provision. In the UK-
based analysis, Pandor et al. [4] included a unit cost of
GBP0.30 (2001 prices) cost per baby screened to account
for the extra (incremental) time taken by a midwife to
explain the test and gain consent, although the actual length
of additional time was not specified. This cost was iden-
tified through a consultation with a midwife. Simpson et al.
[57] provided a similar incremental cost of ‘‘counselling
time required to gain consent’’ for one extra condition. The
value of 2.1 min was obtained through a survey conducted
by the lead author. This gave an additional cost of GBP0.40
(1998 prices) per child screened.
The evaluation conducted by Geelhoed et al. [50], based
in Western Australia, included a cost for the 15 min per
child that a nurse would spend providing information about
the test. An individual figure for the cost of providing in-
formation was not given but it can be calculated by taking
the total cost of nursing input in sample collection (AUS
$326,875), dividing it by the number of babies seen
(25,000) and multiplying this by the proportion of nurse
time spent giving information (0.5), giving a figure of AUS
$6.54 (2001 prices) per child screened. This study clearly
assumed that a greater amount of time was needed to ex-
plain carrier status in the context of cystic fibrosis. As
Australia operates an informed refusal system of informed
consent, this cost is unlikely to account for time taken to
receive consent.
Wildhagen et al. [62], based in The Netherlands, also
evaluated a cystic fibrosis NBSP. This study calculated the
cost of information provision by using the mass media
costs of information provision for a breast cancer screening
programme. The analysis assumed that the relative cost of
providing an NBSP compared with a breast cancer
screening programme would be reduced by a figure of
40 % to account for the greater ease of introducing new-
born screening into clinical practice. The final value in-
cluded in the analysis was GBP 136,956.60 (1996 prices),
which was then combined with the cost of providing in-
formation at the individual level (assumed to be GBP 1.19).
This resulted in a cost of information of GBP 2.13 (1996
prices) per child screened. As this paper was investigating
the introduction of a screening programme, no particular
consent model was assumed and no cost of obtaining
consent was included.
Finally, Autti-Ra¨mo¨ et al. [38] included a cost of EUR
303,000 (2002 prices) for information provided in preg-
nancy about newborn screening. Given a cohort of 56,000
newborns, this would mean a cost of EUR 5.41 per new-
born screened. This cost accounts for the resources needed
for a nurse to give the information along with a leaflet and
for ten percent of parents having an additional consultation
with a physician. Unit costs were not provided for each of
these components. The authors also account for the cost of
gaining consent before the test but as this is combined with
the cost for taking the sample and sending it to the
laboratory, a unit cost cannot be given for consent alone.
No source was given for these costs and they are based on
general assumptions that have been made by the authors.
The lead author later highlights this in a conference ab-
stract describing the difficulties of evaluating newborn
screening interventions stating that ‘‘The original assump-
tions on costs were fictional’’ [66].
A further two studies explicitly mentioned the omission
of the cost of information provision in their evaluation of a
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NBSP. Hamers and Remeau-Pichon’s [52] economic
evaluation of universal screening for MCADD in France,
included the start-up costs of the programme but excluded
the costs of ‘‘producing information and education mate-
rials’’. No justification for this omission was given. Van der
Akker-van Marle et al. [59] explained that they did not
include information provision in their model of the cost
effectiveness of differing methods of screening for cystic
fibrosis because the assumed cost of updating the infor-
mation leaflet would be insignificant.
3.7 Costs of Imperfect Information Provision
Inappropriate, or imperfect, information provision may
lead to further costs to the health service and parents as a
‘knock on’ consequence (or sequelae) of anxiety induced
by poor information [16, 17, 32]. For example, parents who
do not have a clear understanding about their child’s con-
dition, or are overly anxious about their child’s health,
may, as a consequence, subsequently require healthcare
resources and seek frequent consultations with clinicians to
allay their fears [16]. At times specialist consultations are
required as trust has been broken between parents and
health professionals [32]. Only one study [44] mentioned
costs related to the impact of imperfect information, which
was specifically made in reference to false-positive results,
and where a part of the resulting anxiety may possibly be
attributed to a lack of understanding. Schoen et al. [44] (p.
785) identified that whilst false-positive results could cause
increased parental anxiety, the results may also lead to ‘‘a
cascade of costly clinical events, including emergency
department visits, hospital admissions, additional definitive
laboratory studies, and use of on-call medical personnel’’.
Chan et al. [49] also highlighted that children with false-
positive results would face additional costs from misdiag-
nosis and subsequent induced anxiety in parents. They
assumed that ‘‘this cost is transient and can be minimised
by educating providers and parents’’. Despite this, the costs
of providing this information were omitted from their
model of the cost effectiveness of newborn screening for
SCID.
3.8 (Dis)-Benefits of Imperfect Information
Provision
A lack of good understanding of NBS amongst parents may
also lead to quantifiable dis-benefits, or negative outcomes,
of screening. These negative outcomes should be de-
scribed, identified and valued appropriately and distin-
guished from the impact on healthcare resource use to
avoid ‘double-counting’. One theme which appeared in the
identified literature was that false-positive results could be
a potential source of such dis-benefits in that they cause
anxiety for the parents of children receiving them that may
impact on health gain and be captured as a dis-utility.
Whilst receiving such results may naturally cause a certain
degree of stress, anxiety may be exacerbated by a lack of
information provision about the meaning of a false-positive
result. Two of the studies in this review highlighted a link
between the level of information a parent had received
about newborn screening and the magnitude of the anxiety
they would experience on receipt of a false-positive result
[17, 46]. These studies argued that the more informed a
parent was about screening, the lower the anxiety they
would experience upon receipt of a false-positive result.
The remaining studies (n = 25) did not explicitly state
the link between false-positive results and anxiety but some
did include valuations of parental anxiety or made refer-
ence to its potential impact. If improved parental under-
standing does mitigate some of the stress (induced anxiety)
caused by false-positive results, potential reductions in
anxiety, captured in the ‘quality-adjustment (utility)’
component of QALYs should be quantified in the outcome
side of the calculation of relative cost effectiveness of the
screening programme.
One example of a valuation of parental disutility was
identified in a previous study by Prosser et al. [67]. These
authors used the time trade-off approach and showed that
on average, parents were willing to give up 1 week of their
life in order to not receive false-positive results, which
yielded an estimate of a quality of life loss of 0.003.
Prosser et al. [6] included this estimate in a model of
newborn screening for MCADD but found that the result-
ing 0.0005 QALYs lost from false-positive results made no
significant impact on the cost-effectiveness conclusion.
This QALY value would indicate that disutility of false-
positive results is experienced for 2 months, although this
was not clearly stated in the paper. In absolute terms, in-
cluding this dis-benefit raised the incremental cost-effec-
tiveness ratio by GBP50 per QALY.
Venditti et al. [47] conducted a cost-effectiveness ana-
lysis of screening for MCADD, and reported that they
couldn’t find a published value for anxiety caused by false-
positive results in newborn screening. Therefore, they used
a value based on the anxiety that oncology patients expe-
rience when receiving false-positive results experienced
over 3 months. This value was varied between 0.01 and
0.03 in the sensitivity analysis, which resulted in a QALY
loss of between 0.0025 and 0.0075. Introducing this disu-
tility into the model did not significantly affect the results.
The 0.03 value for disutility used in Venditti et al. [47]
was also used in two more recent evaluations of newborn
screening in Texas [58] and Canada [39]. Both studies used
the three month time horizon which was used in the source
paper to calculate the QALY loss from false-positive
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results. In the 2012 study, the authors allowed the effect of
parental anxiety to vary from a disutility of 0.01 to a value
of 0.05 (a QALY loss of 0.0125). Although the dis-benefit
of parental anxiety was included, the authors do not explain
the implications of including it with regards to the cost-
effectiveness conclusions of the analysis. In the Canadian-
based study, the output from the analysis is reported as a
cost per life-year saved. However, the authors do report
that the analysis included a disutility to account for par-
ental anxiety but did not report this as a quality adjustment
to the stated cost per life-year saved. The analysis appeared
to have a significant impact on the cost per life-year saved
when screening was for 15 conditions, making the result
appear less cost effective, but this was probably due the
incorrect application of utility decrements to life years. A
decrement of 0.01–0.03 was applied to the life-years ac-
crued by parents rather than using a utility decrement of
0.01–0.03. The duration of 3 months for the disutility did
not appear to have been accounted for and this would have
reduced the impact of false-positive results. In this way the
paper may be overstating the negative impact of receiving
false-positive results.
Despite directly highlighting the need to provide infor-
mation to reduce the anxiety parents feel on receipt of
false-positive results, Pandor et al. [43], did not include an
explicit value to quantify the impact of this ‘harm’ in their
model. The authors justified this omission by stating that
any psychological dis-benefits caused by screening would
be far outweighed by the improvement in quality of life for
children that a screening programme would bring. In a later
paper by the same authors, Pandor et al. [4] used a similar
argument for the omission of a quantified harm. However,
they further developed the argument by stating that the
ratio of false-positives to true-positives is 3:1 and hence the
psychological harm from a false-positive result would have
to be at least one-third of the psychological benefit from a
true-positive to make a difference on the results of the
analysis.
Two studies assumed that the disutility associated
with parental anxiety would be negligible and so omit-
ted the parameter from their model. In Geelhoed et al.
[50] no cited evidence was given to support the omis-
sion, but they did suggest that only five children had
received false-positive results in Western Australia in
2001 and this would mean the total ‘‘negative benefit’’
of the screening programme would be small. Hamers
and Rumeau-Pichon [52] also excluded anxiety because
of its negligible potential impact and cited papers from
the USA which suggested that parents had a high tol-
erance for false-positive results and that including them
in a model made no significant difference to the
outcome.
4 Discussion
This review identified a relatively low number of published
economic evaluations of NBSP and screening technologies
given the extent of national screening programmes on a
global basis. Around half of the identified studies focussed
on understanding the economic impact of newborn
screening as a national programme. Of these studies, half
were based in countries (Australia, France and The
Netherlands) that all require parental consent prior to per-
forming a newborn screening test. The need for parental
consent infers an explicit need for a clear mechanism of
information provision to be built into a national NBSP and
has associated resource use implications and a potential to
impact on the overall effectiveness of the programme and
that parents should be able to make a choice about whether
to participate in the programme. Even in countries where
screening is mandatory, there is evidence of a clear demand
for parental information [23, 68].
The advent of new technologies has meant it is now
possible to expand the number of conditions included in an
NBSP. The UK has recently almost doubled the number of
conditions screened for [69] with more potential additions
being debated. Internationally, there is continuous pressure
to increase the number of conditions included in pro-
grammes. This expansion in the scope and scale of an
NBSP involving informed consent will have direct resource
use implications in terms of the required use of healthcare
staff to provide information to parents, affect the potential
use of subsequent healthcare resources, and have an impact
on parents. Robust methods of economic evaluation are
needed to quantify the impact of expanding newborn
screening programmes in terms of the health gain to neo-
nates and also the impact on parents and wider families.
Furthermore, the impact on healthcare resources associated
with information provision and subsequent use of follow-
up services needs to be robustly identified and quantified to
understand the full opportunity cost of expanding a new-
born screening programme. Especially considering subop-
timal communication does appear to have an impact on the
overall cost of a NBSP, even if this does not necessarily
mean that they are not cost effective.
Existing economic evaluations have not generally con-
sidered the healthcare costs or impact on parents of infor-
mation provision as part ofNBSP. Just five studies included a
cost of information provision in their evaluation. A further
three papers accounted for the potential effect of imperfect
information provision and the impact on total health gain by
capturing the disutility attached to parental anxiety. If the
relevant parameters to quantify the impact of information
provision in an economic evaluation of NBS are omitted, an
implicit assumption is being made that parents, acting as
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advocates for their newborn, fully understand the benefits
and costs of the NBSP, will always make informed decisions
about whether or not to consent to screening and subse-
quently use healthcare resources appropriately. Yet, this
does not fit with the evidence [70]. A lack of information and
knowledge about the informed consent process has the po-
tential to create additional subsequent costs whichwill not be
quantified when economic evaluations assume that infor-
mation provision is perfect and results in behaviours such as
use of healthcare services. Importantly, when expanding a
programme to include more conditions, the potential for
increased costs associated with the time element of infor-
mation provision should also be taken into account. On a
population level, information provision costs are likely to be
substantial and conclusions regarding the relative cost ef-
fectiveness of a introducing an expanded NBSP are likely to
be influenced by this additional cost.
Expanding a newborn screening programme introduces
a key element of uncertainty for parents. Parents have to
make a decision about whether to participate in the newly
expanded screening programme and also whether to screen
for all the conditions now included. The process of ex-
panding the NBSP has introduced the need for parents to
understand additional, potentially complex, detail on the
relative harms and benefits of screening for each condition.
This information must be explained sufficiently by the
person taking informed consent and must be read, digested
and understood by the parent making the informed consent
on behalf of the newborn baby. If sufficient information, or
the process of providing the information, is not available
then parents could be seen as making an uninformed
choice. An informed choice would be made if more ap-
propriate and tailored information were made available as
part of the NBSP. Indeed there are repeated findings that
people fail to appreciate the personal relevance of NBSP
information and may opt out of screening [16, 71]. Alter-
natively, parents may consent to screening, but then ex-
perience high levels of anxiety and seek further services
when they receive results which do not fit with their ex-
pectations (i.e. positive, false-positive or carrier) [32].
There is evidence, therefore, that insufficient information
provision does have an impact on parents but this review
has shown that there are few attempts to quantify the im-
pact of information provision in published economic
evaluations of expanded NBSP.
Inaccurate test results are likely to yield some anxiety in
parents. Some degree of anxiety is appropriate in these
circumstances but the impact of poor understanding of the
implications of the test result may cause inappropriately
sustained levels of anxiety leading to a measurable impact
on health status of the parent [32]. Not only parents of
newborns with an equivocal first result (commonly, re-
ferred to as a false-positive result) will experience
momentary phases of anxiety. The true incidence of false-
positive results, including the initial screening test and
follow-up confirmatory test used in an NBSP, is likely to be
extremely low. A more relevant concern will be any si-
tuation where the health professional must return to the
parents be it for an initial equivocal test result that requires
a follow-up test, or a new sample, to be carried out that also
implies the need for repeat communication with the parents
of the newborn. There is an increasing suggestion that
whenever there is a need for a health professional to return
to families for further samples (such as when the sample
has been taken incorrectly) this can trigger parents to be-
come quantifiably anxious and potentially reassess their
engagement with screening. It has also been shown that
parents receiving carrier results go through a similar phase
of anxiety when waiting for confirmatory results of carrier
status of cystic fibrosis [32]. There is, therefore, an argu-
ment that balancing the benefits compared with the cost of
‘false-positive’ test results is not a useful analytic ap-
proach. Rather it is necessary to identify and quantify the
opportunity cost of repeat communication cases. This fits
with an ongoing debate and the increasing call to stop using
the term ‘‘false-positive’’ in the context of NBSPs as the
terminology is of limited utility in this clinical context.
Anxiety and service use when waiting for test results
regarding carrier results have been shown to be lower in
parents who are adequately prepared and when communi-
cation is effective [32]. Whilst the studies [6, 39, 47, 58] in
this review suggested that the impact of such anxiety may
be relatively small when quantified in terms of relative
health loss (as a utility value), there may still be an effect
on the cost-effectiveness estimate and particular care
should be made to take this into account when evaluating
expanded programmes or technologies which may increase
not only the false-positive rate, but the number of ‘‘repeat
communication’’ cases. Furthermore, there are concerns
that this is not adequately being accounted for in terms of
resource use as there are numerous papers examining the
impact of communication which suggest that there are real
impacts on wider families [32].
We argue that the costs and dis-benefits from information
provision should be included in economic evaluations of
expanded NBS. However, we also recognise the method-
ological and practical challenges that this requirement to
capture the costs and benefits of information provision in-
troduces. There is limited evidence on the actual resource
implications associated with information provision as part of
NBSP and the potential impact on resource use if a pro-
gramme was expanded. An ongoing study, funded as part of
the UK National Institute for Health Research Health
Technology Assessment programme [72] is currently gen-
erating these data for England, which would be needed to
appropriately populate an economic evaluation. However,
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the requirements for non-English healthcare systems are
likely to be different and country-specific data will be
needed. There are no current data on the on the impact of poor
information and false-positive results on the subsequent use
of healthcare resources as a result of expanded NBSP, which
is a substantial topic for further research.
Traditional units of measurements in economic evalua-
tions assess the impact on health status using life-years saved
or QALYs, which do include the impact on anxiety. The
impact of anxiety in terms of QALYs is generally built up
from a direct assessment of the utility associated anxiety,
such as the time trade-off method used by Prosser et al. or by
using an indirect measure of anxiety such as the health status
measure the EQ-5D [73]. However, this focus on health
status does not capture the impact on informed decision
making per se and some commentators have suggested the
need to extend beyond capturing the impact on health status
alone by using measures of capability (or empowerment) to
capture the impact of complex interventions, such as genetic
testing or screening, on the ability to make an informed de-
cision [65]. Using a measure that values the ability to make
an informed decision as cognitive capability allows the
analyst to capture non-health aspects of effective informa-
tion provision. Measures of capability and associated
population tariffs are available, such as the ICECAP-A [74].
Further methodological work is needed to understand if, and
how, such measures can be used in the context of economic
evaluations used to inform resource allocation in national
healthcare systems. Specifically, it is necessary to under-
stand how society values the relative benefits attached to
health and non-health aspects of interventions [65]. Other
evaluative approaches, such as discrete choice experiments
and contingent valuation methods, have been suggested as a
means of valuing the impact of informed decisionmaking by
estimating willingness to pay [75]. Using these methods to
elicit willingness to pay could capture aspects such as the
process utility [76] (value of how and by whom information
is provided) in addition to the outcome [value of the (dis)
benefit from the information]. Discrete choice experiments
and contingent valuation have limited current practical ap-
plication as they introduce a new evaluative framework of
cost-benefit analysis, which is not consistent with the
evaluation methods used in most national jurisdictions to
inform resource allocation decisions [77].
5 Conclusion
This review has systematically identified if, and how,
published economic evaluations of NBSP and screening-
related technologies have taken account of the information
provision as part of the informed consent process. There is
a limited evidence base that quantifies the impact of
information provision on the healthcare costs and impact
on users of NBSP—the parents of newborns. We suggest
that economic evaluations of expanded NBSP need to take
account of information provision otherwise the impact on
healthcare costs, newborns and their parents will be un-
derestimated. To take this forward, however, research is
needed to generate robust data on the actual cost of in-
formation provision for healthcare services, the impact of
NBSP on subsequent use of healthcare services, par-
ticularly when a repeat communication event occurs, and
also the impact on parents’ health caused by increased
anxiety levels and ability to make an informed decision in
the context of expanded NBSP.
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